Results 91 to 100 of about 53,590 (235)

SPAG6 overexpression decreases the pro-apoptotic effect of daunorubicin in acute myeloid leukemia cells through the ROS/JNK MAPK axis in a GSTP1-dependent manner

Frontiers in Pharmacology
IntroductionAs a malignant hematological disease, the incidence of acute myeloid leukemia (AML) has exhibited an upward trend in recent years. Nevertheless, certain limitations persist in the treatment of AML.
Jie Luo, Li Ding, Shirui Pan, Jing Luo, Haiqiu Zhao, Jiaxiu Yin, Rong Su, Jiamin Zhang, Lin Liu   +8 more
doaj   +1 more source

Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia [PDF]

, 2015
Despite aggressive chemotherapy, approximately one-third of children with acute myeloid leukaemia(AML) relapse. More effective treatments are urgently needed.
Burow, Rachel, Hallahan, Andrew R., Hong, Priscilla, Little, Erica B., Liu, Alfred K. S., Moore, Andrew S., Smith, Amanda M., Stinson, Caedyn, Zivanovic, Andjelija   +8 more
core   +1 more source

Overexpression of the protein kinase CK2 increases the survival and resistance to chemotherapy of acute myeloid leukemia cells [PDF]

, 2013
Background: The critical role of protein kinase CK2 in the regulation of cellular apoptosis suggests its may be involvement in tumor cell resistance to both conventional and unconventional therapies.
PAVAN, LAURA
core   +1 more source

Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia [PDF]

, 2003
Resistance of leukemic cells to chemotherapeutic agents is associated with an unfavorable outcome in pediatric acute lymphoblastic leukemia (ALL).
Boer, M.L. (Monique) den, Holleman, A. (Amy), Janka-Schaub, G.E. (Gritta), Kazemier, K.M. (Karin), Pieters, R. (Rob)   +4 more
core   +3 more sources

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

European Journal of Haematology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Marco Fiorillo, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin–GnRH-III conjugates developed for targeted drug delivery

Beilstein Journal of Organic Chemistry, 2018
Gonadotropin releasing hormone-III (GnRH-III), a native isoform of the human GnRH isolated from sea lamprey, specifically binds to GnRH receptors on cancer cells enabling its application as targeting moieties for anticancer drugs.
Sabine Schuster, Beáta Biri-Kovács, Bálint Szeder, Viktor Farkas, László Buday, Zsuzsanna Szabó, Gábor Halmos, Gábor Mező   +7 more
doaj   +1 more source

Quercetin as a Potential Modulator of P-Glycoprotein Expression and Function in Cells of Human Pancreatic Carcinoma Line Resistant to Daunorubicin

Molecules, 2010
P-glycoprotein (P-gp) is one of the ABC transporters responsible for the resistance of several tumours to successful chemotherapy. Numerous agents are capable of interfering with the P-gp-mediated export of drugs but unfortunately most of them produce ...
Piotr Dziegiel, Magdalena Chmielewska, Maciej Zabel, Sylwia Borska, Miroslaw Sopel   +4 more
doaj   +1 more source

In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour [PDF]

, 1993
Colon tumours are intrinsically resistant to chemotherapy and most of them express the multidrug transporter P glycoprotein (Pgp). Whether this Pgp expression determines their resistance to anticancer agents in patients is not known.
Bruijn, E.A. (Ernst) de, Durante, N.M.C., Eggermont, A.M.M. (Alexander), Gheuens, E.E.O. (Eric), Marquet, R.L. (Richard), Oosterom, A.T. (Allan) van, Vrie, W. (Wim) van de   +6 more
core   +1 more source

Long‐Term Clinical and Molecular Dynamics in Hypoplastic Myelodysplastic Neoplasia Treated With Immunosuppressive Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Myelodysplastic neoplasia (MDS) comprises heterogeneous clonal hematologic disorders characterized by peripheral cytopenia, bone marrow dysplasia, and a risk of leukemic transformation. A hypoplastic variant (MDS‐h) shares features with aplastic anemia and responds to immunosuppressive therapy (IST).
Hannes Treiber, Christina Ganster, Katayoon Shirneshan, Katharina Rittscher, Elzbieta Brzuszkiewicz, Justin Hasenkamp, Wolfram Jung, Gerald Wulf, Detlef Haase   +8 more
wiley   +1 more source

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties

International Journal of Nanomedicine, 2019
Lawrence D Mayer, Paul Tardi, Arthur C LouieJazz Pharmaceuticals, Inc., Palo Alto, CA, USAAbstract: Combination regimens are a standard of care for many cancers.
Mayer LD, Tardi P, Louie AC
doaj